Clinical trial
Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and…
NCT00303550 · Arpida AG, Industry · Completed
Key facts
| NCT number | NCT00303550 |
|---|---|
| Title | Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2) |
| Official title | Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections (ASSIST-2) |
| Lead sponsor | Arpida AG, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Skin Diseases, Bacterial |
| Intervention type | Drug |
| Interventions | Intravenous iclaprim, Intravenous linezolid |
| Start date | Mar 1, 2006 |
| First posted | Mar 17, 2006 |
| Last update posted | Mar 27, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: